Frontiers in Microbiology (Nov 2024)
Suppressed oncogenic molecules involved in the treatment of colorectal cancer by fecal microbiota transplantation
- Xing Han,
- Xing Han,
- Xing Han,
- Bo-Wen Zhang,
- Bo-Wen Zhang,
- Bo-Wen Zhang,
- Wei Zeng,
- Meng-Lin Ma,
- Ke-Xin Wang,
- Bao-Juan Yuan,
- Bao-Juan Yuan,
- Bao-Juan Yuan,
- Dan-Qi Xu,
- Dan-Qi Xu,
- Dan-Qi Xu,
- Jia-Xin Geng,
- Jia-Xin Geng,
- Jia-Xin Geng,
- Chao-Yuan Fan,
- Chao-Yuan Fan,
- Chao-Yuan Fan,
- Zhan-Kui Gao,
- Zhan-Kui Gao,
- Zhan-Kui Gao,
- Muhammad Arshad,
- Muhammad Arshad,
- Muhammad Arshad,
- Shan Gao,
- Liangliang Zhao,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Xiao-Qin Mu,
- Xiao-Qin Mu,
- Xiao-Qin Mu,
- Xiao-Qin Mu
Affiliations
- Xing Han
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Xing Han
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Xing Han
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Bo-Wen Zhang
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Bo-Wen Zhang
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Bo-Wen Zhang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Wei Zeng
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Meng-Lin Ma
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Ke-Xin Wang
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Bao-Juan Yuan
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Bao-Juan Yuan
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Bao-Juan Yuan
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Dan-Qi Xu
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Dan-Qi Xu
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Dan-Qi Xu
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Jia-Xin Geng
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Jia-Xin Geng
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Jia-Xin Geng
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Chao-Yuan Fan
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Chao-Yuan Fan
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Chao-Yuan Fan
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Zhan-Kui Gao
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Zhan-Kui Gao
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Zhan-Kui Gao
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Muhammad Arshad
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Muhammad Arshad
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Muhammad Arshad
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Shan Gao
- Pathology Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
- Liangliang Zhao
- Department of Colorectal Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, China
- Shu-Lin Liu
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Shu-Lin Liu
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Shu-Lin Liu
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Shu-Lin Liu
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada
- Shu-Lin Liu
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Xiao-Qin Mu
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province), College of Pharmacy, Harbin Medical University, Harbin, China
- Xiao-Qin Mu
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China
- Xiao-Qin Mu
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Xiao-Qin Mu
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- DOI
- https://doi.org/10.3389/fmicb.2024.1451303
- Journal volume & issue
-
Vol. 15
Abstract
Dysbiosis of the intestinal microbiota is prevalent among patients with colorectal cancer (CRC). This study aims to explore the anticancer roles of the fecal microbiota in inhibiting the progression of colorectal cancer and possible mechanisms. The intestinal microbial dysbiosis in CRC mice was significantly ameliorated by fecal microbiota transplantation (FMT), as indicated by the restored ACE index and Shannon index. The diameter and number of cancerous foci were significantly decreased in CRC mice treated with FMT, along with the restoration of the intestinal mucosal structure and the lessening of the gland arrangement disorder. Key factors in oxidative stress (TXN1, TXNRD1, and HIF-1α); cell cycle regulators (IGF-1, BIRC5, CDK8, HDAC2, EGFR, and CTSL); and a critical transcription factor of the innate immune signal pathway (IRF5) were among the repressed oncogenic targets engaged in the FMT treatment of CRC. Correlation analysis revealed that their expressions were positively correlated with uncultured_bacterium_o_Mollicutes_RF39, Rikenellaceae_RC9_gut_group, and negatively correlated with Bacillus, Marvinbryantia, Roseburia, Angelakisella, Enterorhabdus, Bacteroides, Muribaculum, and genera of uncultured_bacterium_f_Eggerthellaceae, uncultured_bacterium_f_Xanthobacteraceae, Prevotellaceae_UCG-001, uncultured_bacterium_f_Erysipelotrichaceae, uncul-tured_bacterium_f_Lachnospiraceae, uncultured_bacterium_f_Ruminococcaceae, Eubacterium_coprostanoligenes_group, Ruminococcaceae_UCG-005, and uncultured_bacterium_f_Peptococcaceae. This study provides more evidence for the application of FMT in the clinical treatment of CRC.
Keywords
- colorectal cancer
- intestinal microbiota
- intestinal homeostasis
- fecal microbiota transplantation
- oncogenic molecules
